Spots Global Cancer Trial Database for antiandrogen therapy
Every month we try and update this database with for antiandrogen therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer | NCT03649841 | Castration-Sens... Metastatic Mali... Metastatic Pros... Prostate Adenoc... Prostate Small ... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Antiandrogen Th... Abiraterone Ace... Prednisone Radiation Thera... | 18 Years - | University of Washington | |
| Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis | NCT01409200 | Metastatic Mali... Prostate Ductal... Stage III Prost... Stage IV Prosta... | Antiandrogen Th... Axitinib Radical Prostat... Regional Lymph ... | 18 Years - | M.D. Anderson Cancer Center | |
| Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer | NCT00244920 | Prostate Cancer | bicalutamide leuprolide acet... squalamine lact... adjuvant therap... antiandrogen th... antiangiogenesi... conventional su... neoadjuvant the... releasing hormo... | 18 Years - | OHSU Knight Cancer Institute | |
| Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer | NCT00967954 | Prostate Cancer | antiandrogen th... releasing hormo... DNA analysis RNA analysis comparative gen... gene expression... laboratory biom... diffusion-weigh... magnetic resona... | - | National Cancer Institute (NCI) | |
| Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery | NCT03541850 | PSA Level Great... PSA Progression Stage I Prostat... Stage II Prosta... Stage III Prost... | Antiandrogen Th... Quality-of-Life... Stereotactic Bo... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer | NCT04947254 | Prostate Carcin... Stage IIC Prost... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IVA Prost... | Abiraterone Ace... Antiandrogen Th... Apalutamide Biopsy Niraparib Prednisone Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer | NCT03649841 | Castration-Sens... Metastatic Mali... Metastatic Pros... Prostate Adenoc... Prostate Small ... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Antiandrogen Th... Abiraterone Ace... Prednisone Radiation Thera... | 18 Years - | University of Washington | |
| Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases | NCT00685646 | Metastatic Canc... Prostate Cancer | antiandrogen th... zoledronic acid | 20 Years - | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | |
| Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone | NCT00392938 | Metastatic Canc... Prostate Cancer | antiandrogen th... docetaxel C-11 acetate PE... F-18 FDG PET sc... Tc-99m bone sca... CT scan of the ... | 18 Years - 120 Years | University of Washington | |
| MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer | NCT05676463 | Prostate Adenoc... Stage IIIB Pros... Stage IIIC Pros... | MRI-guided Inte... Antiandrogen Th... PSMA PET Scan Computed Tomogr... Magnetic Resona... Bone Scan Biospecimen Col... Quality-of-Life... | 18 Years - | Thomas Jefferson University | |
| Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer | NCT03827473 | Castration-Sens... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Antiandrogen Th... Docetaxel Prednisone Quality-of-Life... Questionnaire A... | 18 Years - | University of Utah | |
| Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone | NCT00392938 | Metastatic Canc... Prostate Cancer | antiandrogen th... docetaxel C-11 acetate PE... F-18 FDG PET sc... Tc-99m bone sca... CT scan of the ... | 18 Years - 120 Years | University of Washington | |
| Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery | NCT03541850 | PSA Level Great... PSA Progression Stage I Prostat... Stage II Prosta... Stage III Prost... | Antiandrogen Th... Quality-of-Life... Stereotactic Bo... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial | NCT06244004 | Castration-Sens... Metastatic Pros... Stage IVB Prost... | Antiandrogen Th... Bone Scan Computed Tomogr... Cytotoxic Chemo... FDG-Positron Em... Radiation Thera... | 18 Years - | Northwestern University | |
| Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer | NCT00104715 | Prostate Cancer | antiandrogen th... docetaxel goserelin aceta... orchiectomy | 18 Years - 120 Years | UNICANCER | |
| Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer | NCT00918385 | Prostate Cancer | Nilutamide Dasatinib | 18 Years - | Duke University | |
| FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial | NCT06244004 | Castration-Sens... Metastatic Pros... Stage IVB Prost... | Antiandrogen Th... Bone Scan Computed Tomogr... Cytotoxic Chemo... FDG-Positron Em... Radiation Thera... | 18 Years - | Northwestern University | |
| Post-operative or Early Salvage XRT and ADT for High Risk PCa | NCT00949962 | Prostate Cancer | antiandrogen th... leuprolide acet... 3-dimensional c... | - 80 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Androgen Deprivation Therapy in Treating Patients With Prostate Cancer | NCT00110162 | Prostate Cancer | antiandrogen th... releasing hormo... orchiectomy | - | National Cancer Institute (NCI) | |
| Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases | NCT00685646 | Metastatic Canc... Prostate Cancer | antiandrogen th... zoledronic acid | 20 Years - | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | |
| Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | NCT00003517 | Adenocarcinoma ... Stage III Prost... Stage IV Prosta... Recurrent Prost... | antineoplaston ... antineoplaston ... bicalutamide flutamide leuprolide acet... alternative pro... antiandrogen th... biological ther... biologically ba... cancer preventi... complementary a... differentiation... endocrine thera... hormone therapy | 18 Years - | National Cancer Institute (NCI) | |
| FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial | NCT06244004 | Castration-Sens... Metastatic Pros... Stage IVB Prost... | Antiandrogen Th... Bone Scan Computed Tomogr... Cytotoxic Chemo... FDG-Positron Em... Radiation Thera... | 18 Years - | Northwestern University | |
| MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer | NCT05676463 | Prostate Adenoc... Stage IIIB Pros... Stage IIIC Pros... | MRI-guided Inte... Antiandrogen Th... PSMA PET Scan Computed Tomogr... Magnetic Resona... Bone Scan Biospecimen Col... Quality-of-Life... | 18 Years - | Thomas Jefferson University | |
| PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer | NCT02472275 | Stage I Prostat... Stage II Prosta... Stage III Prost... | Antiandrogen Th... Laboratory Biom... Multitargeted T... Radiation Thera... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer | NCT00104715 | Prostate Cancer | antiandrogen th... docetaxel goserelin aceta... orchiectomy | 18 Years - 120 Years | UNICANCER | |
| Androgen Deprivation Therapy in Treating Patients With Prostate Cancer | NCT00110162 | Prostate Cancer | antiandrogen th... releasing hormo... orchiectomy | - | National Cancer Institute (NCI) | |
| FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial | NCT06244004 | Castration-Sens... Metastatic Pros... Stage IVB Prost... | Antiandrogen Th... Bone Scan Computed Tomogr... Cytotoxic Chemo... FDG-Positron Em... Radiation Thera... | 18 Years - | Northwestern University | |
| Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases | NCT00685646 | Metastatic Canc... Prostate Cancer | antiandrogen th... zoledronic acid | 20 Years - | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | |
| Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer | NCT03456843 | Stage IV Prosta... | Antiandrogen Th... Docetaxel Laboratory Biom... Quality-of-Life... Questionnaire A... Radical Prostat... | 18 Years - | Yale University | |
| Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer | NCT03456843 | Stage IV Prosta... | Antiandrogen Th... Docetaxel Laboratory Biom... Quality-of-Life... Questionnaire A... Radical Prostat... | 18 Years - | Yale University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
